Dapagliflozin for Failing Fontan Circulation
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a Fontan procedure (a surgery for a single-ventricle heart condition).
- You have shortness of breath (NYHA class II-IV) that is not from another cause like lung disease or a heart attack.
- You have high pressure in your veins as measured during a test (≥20 mmHg).
- You are not taking certain medications like insulin, empagliflozin, or canagliflozin, and you do not have type 1 diabetes or severe kidney/liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
This trial tests if dapagliflozin, a medication usually used for diabetes, can help people with acute heart failure recover heart function. If you are in the hospital for heart failure, this study will check if the drug improves how your heart squeezes.
This trial tests whether adding dapagliflozin (a medication that helps protect the heart and kidneys) helps people with heart failure who are also on peritoneal dialysis. It may offer extra support for your heart and kidney health.
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
Hear when a new Fontan Circulation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.